Life Sciences DNA Podcast

Turning Data and AI Into Better Business Outcomes

Artificial intelligence is reshaping how biopharmaceutical companies discover, develop, commercialize, and support medicines. But realizing its potential requires far mor

Measuring AI by Business Results in Life Sciences

Artificial intelligence is creating new opportunities to improve clinical development, but successful adoption requires more than choosing the latest model or launching i

Lessons from Insmed’s Journey to an AI First Biotech

Chris Colucci, vice president of information technology at Insmed, sits down with Nagaraja Srivatsan to discuss the company’s shift from AI experimentation to enterprise-

Making AI Transformations that Stick

Vikram Nair, chief information officer of Amneal Pharmaceuticals, joins Srivatsan Nagaraja to break down what it really takes to turn AI from boardroom buzz into real bus

Finding ROI from AI in the Mundane

Dennis Salotti, executive director and head of clinical outsourcing and innovation at Jazz Pharmaceuticals, joins Srivatsan Nagaraja to talk about what AI really looks li

A Pragmatic Path to AI-Enabled Commercial Operations

Tris Pharma Chief Commercial Officer Manesh Naidu sits down with Nagaraja Srivatsan to discuss how the small but growing specialty pharma company is pursuing a deliberate

Reimagining Scientific Work in the Age of AI Agents

Shweta Maniar, global strategy and market leader for life sciences at Google Cloud, sits down with Nagaraja Srivatsan to unpack what it takes to turn AI pilots into durab

Orchestrating Scientists, Data, and AI to Discover New Drugs

Scotch McClure had a bold plan for Maxwell Biosciences to map and mine the roughly 3 percent of peptides circulating in human plasma. The company has harnessed AI to move

Scaling Practical AI Across Commercial Teams

Drew McCormick, head of data and analytics at Eversana, sits down with Nagaraja Srivatsan to trace the company’s AI journey from classic predictive modeling in its data a

Building an AI-Ready Biopharma Organization

Scott Cenci, chief information and data officer for Acadia Pharmaceuticals, sits down with Nagaraja Srivatsan to discuss how generative and agentic AI are reshaping bioph

Automating Biopharma Workflows with AI and Robotics

Karthik Raman, co-founder and CEO of Persist AI, sits down with the Nagaraja Srivatsan to discuss how robotics, AI, and cloud tech are supercharging drug formulation to a

De-Risking Discovery and Improving the Success Rates of Drug Development with AI

Gabi Tarcic, vice president of product for Evogene, sits down with Srivatsan Nagaraja about applying AI to small molecule drug discovery, the cultural and operational cha

Agents of Change: Creating Regulatory Documents with AI

Anita Modi, CEO and founder of Peer AI, joins Srivatsan Nagaraja to discuss the transformative impact of agentic AI on document creation for pharmaceutical companies. She

Redefining Biomarkers for Immune-Mediated Disease with AI

Ronel Veksler, co-founder and CEO of PromiseBio, sits down with Amar Drawid to discuss the company’s AI-enabled proteomics platform, and how post-translational modificati

Driving Insights from Real World Oncology Data with AI

Aaron Cohen, Head of Research Oncology, Clinical Data for Flatiron Health, sits down with Amar Drawid to discuss Flatiron’s use of large language models to extract and an

Improving Drug Development with Real-World Data

Manfred Stapff, founder and principal of Candid Advisory, sits down with Amar Drawid to discuss the potential of real-world data to accelerate drug development and improv

Navigating the AI Landscape in Clinical Development

Stephen Pyke, chief clinical data and digital officer at Parexel, sits down with Srivatsan Nagaraja to discuss the adoption of AI technologies in clinical development. He

Transforming Cancer Diagnostics and Care with AI

Mohan Uttarwar, CEO 1Cell.Ai, sits down with Amar Drawid to discuss how his company is transforming cancer diagnostics and care by combining cutting-edge molecular scienc

Moving Beyond the Hype of AI in Biopharma

Amar Drawid, vice president and global head of data analytics, insights, and AI for BioNTech, sits down with Nagaraja Srivatsan to discuss the evolution, adoption, and ch

Why AI’s Most Promising Near-Term Value Is in Clinical Operations

Dimitris Agrafiotis, director of digital analytics and AI at Arsenal Capital Partners sits down with Nagaraja Srivatsan to discuss the current state of AI in clinical tri